Platform
Home
Screener
Copilot
AskEdgar Studio
New
Back
Ernexa Therapeutics Inc.
ERNA · SEC Filings
website
5
Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, spe...
Price
2.05
Market Cap
3.47 M
Float
1.41 M
Country
US
Sector
Healthcare
Exchange
NASDAQ
Overview
Filings
Insights
Dilution
News
Transcripts
Search in Documents
Open in Studio
Studio
Login
Ask about ERNA
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
All
Chronological
Financials
Registrations
Prospectus
News
Proxies
Ownerships
Other
Ernexa Therapeutics Inc.
ERNA · SEC Filings
1.41 M
Float
2.05
Price
3.47 M
Market Cap
Financials
TYPE
HEADLINE
FILED AT
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 6, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 6, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 11, 2026
10-K
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 13, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 7, 2025
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 13, 2025
News
TYPE
HEADLINE
FILED AT
8-K
Ernexa Therapeutics Inc. Releases Investor Presentation
Oct 15, 2026
8-K
Ernexa Therapeutics Releases Corporate Fact Sheet and Investor Presentation
Sep 16, 2026
8-K
Ernexa Therapeutics Inc. Appoints Robert J. Spiegel, M.D. to Board of Directors
Sep 16, 2026
8-K
Ernexa Therapeutics Inc. Releases Updated Investor Presentation
Jul 2, 2026
8-K
Ernexa Therapeutics Inc. Announces Results of 2026 Annual Meeting of Stockholders
Jul 2, 2026
8-K
Ernexa Therapeutics Inc. Announces Resignation of Senior Vice President of Finance
Jun 26, 2026
Prospectus
TYPE
HEADLINE
FILED AT
Registrations
TYPE
HEADLINE
FILED AT
S-3/A
March 2026 SHELF + ATM | Float: 22,374,863
Mar 24, 2026
S-3
March 2026 SHELF + ATM | Float: 22,374,863
Mar 13, 2026
8-A12B
Form 8-A12B - Registration of securities [Section 12(b)]
Feb 5, 2026
S-1/A
SPA
Feb 5, 2026
S-1/A
SPA
Feb 3, 2026
S-1
OFFERING (Best Efforts) - Brookline
Feb 2, 2026
Proxies
TYPE
HEADLINE
FILED AT
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
May 11, 2026
DEF 14A
Form DEF 14A - Other definitive proxy statements
May 11, 2026
DEF 14C
Form DEF 14C - Other definitive information statements
Apr 13, 2026
PRE 14C
Form PRE 14C - Other preliminary information statements
Apr 1, 2026
DEF 14A
Form DEF 14A - Other definitive proxy statements
Apr 14, 2025
PRE 14A
Form PRE 14A - Other preliminary proxy statements
Apr 3, 2025
Ownerships
TYPE
HEADLINE
FILED AT
SCHEDULE 13G/A
Freebird Partners LP (Filed by)
Oct 30, 2026
3
Spiegel Robert J. (Reporting)
Sep 22, 2026
4
Bristol James Arthur (Reporting)
Sep 1, 2026
4
Cicala Peter (Reporting)
Sep 1, 2026
4
Polinsky David (Reporting)
Sep 1, 2026
4
Wexler William A. (Reporting)
Sep 1, 2026
Chronological
TYPE
HEADLINE
FILED AT
Other
TYPE
HEADLINE
FILED AT
EFFECT
Form EFFECT - Notice of Effectiveness
Mar 31, 2026
CORRESP
Form CORRESP - Correspondence
Mar 26, 2026
LETTER
Form UPLOAD - SEC-generated letter
Mar 20, 2026
EFFECT
Form EFFECT - Notice of Effectiveness
Feb 6, 2026
CORRESP
Form CORRESP - Correspondence
Feb 3, 2026
CORRESP
Form CORRESP - Correspondence
Feb 3, 2026
